



DANIOLABS

DanioLabs wins funding for breakthrough research into drug addiction

Cambridge UK, May 2004. DanioLabs, the UK based therapeutics company has won \$400,000 SBRI funding to take forward its research into novel compounds for the treatment of drug addiction.

Drug abuse in the US was estimated to cost \$245.7 billion in 1992 and is likely to be much higher now. The NIDA have highlighted the complete absence of any medication for the treatment of addiction to cocaine, LSD, PCP, marijuana, anabolic steroids and other stimulants. Such is the need that reprofiled compounds such as Zyban have been used to treat smoking addiction. DanioLabs has shown that its screening system would have picked up Zyban and intends to further this work to find more efficacious drugs.

Paul Goldsmith, Chief Scientific Officer and clinical neurologist commented; “We have seen in our other programs that we can rapidly discover candidate drugs with proven clinically relevant effects. We now have the opportunity to build on our pilot work on addiction.”

Notes to Editors

About DanioLabs Ltd

DanioLabs is a therapeutics company that uses its world leading phenotype driven drug discovery technologies to identify novel treatments for a variety of human diseases. A major part of the DanioLabs' platform involves the use of zebrafish as an experimental species. Using these models, the Company is able to identify activity of experimental compounds, and to provide the additional evidence relevant to the treatment of the disease needed to progress such compounds cost-effectively through the drug development process.

DanioLabs build high-throughput disease models that allow 96 well plate format in vivo screening. As well as working with partners to develop new models in a variety of disease areas and to undertake screening campaigns, the Company also uses its systems to identify its own novel therapeutics. For more information on DanioLabs Ltd, please see www.daniolabs.com

Email: info@daniolabs.com